Gland Pharma said that it has got permission from the US Food and Drug Administration to manufacture a generic blood pressure medication. According to a regulatory filing, the Hyderabad-based business has acquired provisional clearance from the US...
Autifony Therapeutics Limited (Autifony), a company that is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, announced a $770.5 million exclusive global licensing agreement with...
Yesafili, a biosimilar of aflibercept, has been given marketing permission by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA), according to Biocon Biologics, a subsidiary of Biocon. In September, Yesafili, received marketing...
Natco Pharma's consolidated net profit climbed fivefold (547%) to Rs 369 crore in the second quarter ended September 30, 2023, from about Rs 57 crore in the same quarter of fiscal year 2022-23. This was on a 134% jump in consolidated total revenue...
The worldwide cell and gene therapy industry is expected to increase significantly, rising from US$ 14.2 billion in 2022 to an anticipated US$ 117.1 billion by 2032, representing a spectacular 24 percent CAGR between 2023 and 2032. According to a...
From the works of Louis Pasteur and Alexander Fleming to the present era of precision medicine and immunotherapy, the field of drug research and development (R&D) has experienced a remarkable advancement in the last two centuries
According to the latest survey by Practo, the leading digital healthcare company in India, 70% of individuals with diabetes
With immediate effect, Lanxess, a specialty chemicals company, will be distributing its Lewatit ion exchange resins and Bayoxide iron oxide adsorbers in France through Caldic,
The CHMP's positive opinion for Uzpruvo is a historic moment as it is the first time the EMA has recommended a biosimilar to the Stelara reference product for authorization.
Pearl Tiwari, director and CEO of Ambuja Foundation, suggests that training and equipping